Showing results (2161-2170 of 2,371) with videos related to

Sort By:
Pageof 238
Future Medicinal Chemistry|November 2, 2013
Development of lysophosphatidic acid pathway modulators as therapies for fibrosisDavid C Budd, Yimin Qian
Future Medicinal Chemistry|November 2, 2013
Targeting the redox metabolism of Plasmodium falciparumFrançoise Nepveu, Francesco Turrini
Future Medicinal Chemistry|December 24, 2013
Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infectionsSubhajit Biswas, Soumi Sukla, Hugh J Field
Future Medicinal Chemistry|July 20, 2017
Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluationManinder Kaur, Manjinder Singh, Om Silakari
Future Medicinal Chemistry|August 10, 2017
Molecular modeling, enzyme activity, anti-inflammatory and antiarthritic activities of newly synthesized quinazoline derivativesHatem A Abuelizz, Anouar El Hassane, Mohamed Marzouk, et al.
Future Medicinal Chemistry|August 11, 2017
A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitorsSolomon Tadesse, Ge Zhu, Laychiluh B Mekonnen, et al.
Future Medicinal Chemistry|October 28, 2017
Activity of gallic acid and its ester derivatives in Caenorhabditis elegans and zebrafish (Danio rerio) modelsJunya de Lacorte Singulani, Liliana Scorzoni, Paulo César Gomes, et al.
Future Medicinal Chemistry|October 28, 2017
CDK5 in oncology: recent advances and future prospectsJimma Likisa Lenjisa, Solomon Tadesse, Nishat Zareen Khair, et al.
Future Medicinal Chemistry|October 28, 2017
New insights for the use of quercetin analogs in cancer treatmentDomenico Iacopetta, Fedora Grande, Anna Caruso, et al.
Future Medicinal Chemistry|August 26, 2017
Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancersElla Lineham, John Spencer, Simon J Morley
Pageof 238